Repligen SEC Filings

Repligen Corp (RGEN) director Anthony Hunt exercised options and sold shares on 09/10/2025 under a documented plan. Mr. Hunt exercised a stock option to acquire 20,000 shares at an exercise price of $33.87, resulting in 20,000 newly acquired shares recorded in Table II. On the same date he sold multiple blocks of common stock under a 10(b)5-1 trading plan, with weighted-average sale prices reported at $116.34, $118.32, $119.64, $120.19, $121.42 and $122.23 for different tranches. After these transactions his direct beneficial ownership of common stock is reported as 100,743 shares and he beneficially owns 182,344 shares underlying options.

Repligen Corp (RGEN) filed a Form 144 reporting a proposed sale of 29,111 common shares through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $3,508,378.25 and approximately 56,257,618 shares outstanding. The filing shows 9,111 shares acquired via restricted stock vesting on 03/01/2022 as compensation, and 20,000 shares associated with options (options granted 03/01/2018) to be sold on 09/10/2025 for cash. The filer reports no sales in the past three months. The notice includes the filer’s attestation that they are not aware of any undisclosed material adverse information about the issuer.

T. Rowe Price Associates, Inc. filed an Amendment No. 6 to Schedule 13G reporting ownership of 3,429,547 shares of Repligen Corp common stock, representing 6.1% of the class. The filing shows T. Rowe Price has sole voting power over 3,170,704 shares and sole dispositive power over 3,429,435 shares. No shared voting or dispositive power is reported.

The filer certifies the shares are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing lists Maryland as the filer’s place of organization and provides issuer and filer addresses.

Repligen Corporation officer Violetta Hughes reported awards and option grants in a Form 4 filing. On 09/02/2025 she was awarded 4,142 restricted stock units, each representing a contingent right to one share; the RSUs vest in equal annual installments over five years beginning on the first anniversary of the grant and will be settled only in shares, so they are reported as 4,142 shares beneficially owned following the transaction. On the same date she acquired a stock option to buy 3,914 shares with an exercise price of $120.69 and an expiration date of 09/02/2035; those options also vest in equal annual instalments over five years. The Form 4 is signed by an attorney-in-fact and filed 09/04/2025.

Repligen Corp (RGEN) insider transaction summary. Olivier Loeillot, who serves as both Director and Chief Executive Officer, reported a transaction dated 09/03/2025 showing 2,506 shares of Repligen common stock were disposed of at a price of $116.18 per share. The filing explains these shares were withheld by the issuer to satisfy tax withholding obligations arising upon the release of restricted stock units. After the withholding, Loeillot beneficially owns 44,187 shares outright. The Form 4 was filed by one reporting person and signed on behalf of Loeillot by Jennifer Carmichael (Attorney in Fact) on 09/04/2025.

Martin D. Madaus, a director of Repligen Corporation (RGEN), reported an insider purchase of 1,800 shares of common stock on 08/08/2025 at a weighted-average price of $112.128 per share. The filing shows those 1,800 shares are beneficially owned and held indirectly through the Martin D. Madaus 2011 Revocable Trust. The Form 4 also lists a disposition of 5,586 shares and indicates 11 shares held indirectly in a spouse trust. The report identifies the filer as a director and provides the weighted-average purchase price and the trustee holdings without additional context on total holdings or prior positions.